Ratings by Piper Sandler (Joseph Catanzaro)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/3/2025 | Immunitybio Inc | IBRX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2025 | Iovanace Biotherapeutics | IOVA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2025 | Schrodinger | SDGR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2025 | Merus N.V. | MRUS | New Coverage | Overweight (N/A) |
40.11 (90.00) |
124.38% | Details | |
| 2/12/2025 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2025 | Turnstone Biologics | TSBX | Downgrade | Neutral (Overweight) |
0.41 (0.36) |
-12.2% | Details | |
| 1/31/2025 | Iovanace Biotherapeutics | IOVA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/17/2025 | Keros Therapeutics | KROS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/10/2025 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 12/13/2024 | Cardiff Oncology | CRDF | Maintain | Overweight (N/A) |
|
Details | ||
| 11/22/2024 | Keros Therapeutics | KROS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2024 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2024 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2024 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2024 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2024 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2024 | ESSA Pharma | EPIX | Downgrade | Neutral (Overweight) |
5.20 (0.20) |
-96.15% | Details | |
| 10/31/2024 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2024 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2024 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/7/2024 | Immatics | IMTX | New Coverage | Overweight (N/A) |
10.35 (9.86) |
-4.73% | Details | |
| 10/1/2024 | Repare Therapeutics | RPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2024 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2024 | Context Therapeutics | CNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2024 | Tango Therapeutics Inc. | TNGX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2024 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2024 | Acrivon Therapeutics Inc | ACRV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2024 | Context Therapeutics | CNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2024 | Repare Therapeutics | RPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2024 | I-Mab | IMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 9/11/2024 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2024 | Context Therapeutics | CNTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2024 | Tango Therapeutics Inc. | TNGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/27/2024 | Aadi Bioscience Inc | AADI | Downgrade | Neutral (Overweight) |
1.58 (2.05) |
29.75% | Details | |
| 8/19/2024 | Turnstone Biologics | TSBX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2024 | LENZ Therapeutics Inc | LENZ | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2024 | Iovanace Biotherapeutics | IOVA | Downgrade | Neutral (Overweight) |
9.43 (5.13) |
-45.6% | Details | |
| 7/15/2024 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 6/18/2024 | Keros Therapeutics | KROS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/7/2024 | Halozyme Therapeutics | HALO | Downgrade | Neutral (Overweight) |
45.65 (67.37) |
47.58% | Details | |
| 6/3/2024 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/29/2024 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/28/2024 | CytomX Therapeutics | CTMX | Upgrade | Overweight (Neutral) |
1.83 (0.53) |
-71.04% | Details | |
| 5/24/2024 | Turnstone Biologics | TSBX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/24/2024 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2024 | Context Therapeutics | CNTX | New Coverage | Overweight (N/A) |
1.71 (3.12) |
82.46% | Details | |
| 4/29/2024 | Immunitybio Inc | IBRX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/25/2024 | Acrivon Therapeutics Inc | ACRV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/22/2024 | Boundless Bio Inc. | BOLD | New Coverage | Overweight (N/A) |
11.30 (1.13) |
-90% | Details | |
| 4/5/2024 | Achilles Therapeutics | ACHL | Downgrade | Neutral (Overweight) |
1.20 (1.48) |
23.33% | Details | |
| 3/27/2024 | LENZ Therapeutics Inc | LENZ | New Coverage | Overweight (N/A) |
16.32 (20.26) |
24.14% | Details | |
| 3/25/2024 | Immunitybio Inc | IBRX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/18/2024 | Leap Therapeutics | LPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2024 | I-Mab | IMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2024 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2024 | Revolution | RVMD | New Coverage | Overweight (N/A) |
31.53 (98.40) |
212.08% | Details | |
| 3/1/2024 | Cardiff Oncology | CRDF | Maintain | Overweight (N/A) |
|
Details | ||
| 2/29/2024 | Schrodinger | SDGR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2024 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2024 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/12/2024 | Tango Therapeutics Inc. | TNGX | New Coverage | Overweight (N/A) |
12.16 (16.95) |
39.39% | Details | |
| 2/7/2024 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 12/27/2023 | Gracell Biotechnologies Inc | GRCL | Downgrade | Neutral (Overweight) |
6.19 (10.25) |
65.59% | Details | |
| 12/15/2023 | Aadi Bioscience Inc | AADI | Maintain | Overweight (N/A) |
|
Details | ||
| 12/4/2023 | Immunogen Inc. | IMGN | Downgrade | Neutral (Overweight) |
29.35 (31.25) |
6.47% | Details | |
| 11/7/2023 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2023 | Repare Therapeutics | RPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2023 | Mirati Therapeutics | MRTX | Downgrade | Neutral (Overweight) |
60.20 (58.70) |
-2.49% | Details | |
| 8/15/2023 | Turnstone Biologics | TSBX | New Coverage | Overweight (N/A) |
12.00 (0.41) |
-96.58% | Details | |
| 8/9/2023 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2023 | Mirati Therapeutics | MRTX | New Coverage | Overweight (N/A) |
28.06 (58.70) |
109.19% | Details | |
| 6/26/2023 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2023 | Rain Therapeutics | RAIN | Downgrade | Neutral (Overweight) |
9.93 (2.80) |
-71.8% | Details | |
| 5/12/2023 | Immunitybio Inc | IBRX | Downgrade | Neutral (Overweight) |
6.22 (8.67) |
39.39% | Details | |
| 5/10/2023 | Halozyme Therapeutics | HALO | Upgrade | Overweight (Neutral) |
30.28 (45.65) |
50.76% | Details | |
| 5/10/2023 | Exelixis | EXEL | New Coverage | Overweight (N/A) |
19.03 (41.55) |
118.34% | Details | |
| 5/5/2023 | Keros Therapeutics | KROS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2023 | Schrodinger | SDGR | New Coverage | Overweight (N/A) |
29.15 (12.74) |
-56.3% | Details | |
| 5/3/2023 | Immunogen Inc. | IMGN | Upgrade | Overweight (Neutral) |
5.20 (31.25) |
500.96% | Details | |
| 4/28/2023 | Gilead Sciences | GILD | New Coverage | Overweight (N/A) |
83.74 (143.93) |
71.88% | Details | |
| 4/3/2023 | I-Mab | IMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2023 | Harpoon Therapeutics | HARP | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2023 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2023 | Iovanace Biotherapeutics | IOVA | Upgrade | Overweight (Neutral) |
7.74 (9.43) |
21.83% | Details | |
| 1/20/2023 | Rain Therapeutics | RAIN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2023 | Leap Therapeutics | LPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2023 | CytomX Therapeutics | CTMX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/20/2022 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2022 | Acrivon Therapeutics Inc | ACRV | New Coverage | Overweight (N/A) |
12.50 (1.41) |
-88.72% | Details | |
| 12/7/2022 | Achilles Therapeutics | ACHL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/21/2022 | Iovanace Biotherapeutics | IOVA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2022 | Oyster Point Pharma | OYST | Downgrade | Neutral (Overweight) |
8.35 (11.17) |
33.77% | Details | |
| 9/13/2022 | Cardiff Oncology | CRDF | Maintain | Overweight (N/A) |
|
Details | ||
| 8/31/2022 | I-Mab | IMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2022 | Harpoon Therapeutics | HARP | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2022 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2022 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2022 | CytomX Therapeutics | CTMX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/7/2022 | CytomX Therapeutics | CTMX | Downgrade | Neutral (Overweight) |
1.94 (1.83) |
-5.67% | Details | |
| 6/2/2022 | Repare Therapeutics | RPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Rain Therapeutics | RAIN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Oyster Point Pharma | OYST | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Neoleukin Therapeutics | NLTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Marker Therapeutics | MRKR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Leap Therapeutics | LPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | I-Mab | IMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Immunitybio Inc | IBRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Harpoon Therapeutics | HARP | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Gracell Biotechnologies Inc | GRCL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Cardiff Oncology | CRDF | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2022 | Achilles Therapeutics | ACHL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2022 | Sensei Biotherapeutics | SNSE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2022 | Connect Biopharma Holdings Ltd | CNTB | Downgrade | Neutral (Overweight) |
1.94 (2.48) |
27.84% | Details | |
| 3/17/2022 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/14/2022 | Harpoon Therapeutics | HARP | Maintain | Overweight (N/A) |
|
Details | ||
| 3/10/2022 | Sensei Biotherapeutics | SNSE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2022 | Figs Inc. | FIGS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/2/2022 | Neoleukin Therapeutics | NLTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2022 | Cardiff Oncology | CRDF | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2022 | Marker Therapeutics | MRKR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2022 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/26/2022 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 1/6/2022 | Connect Biopharma Holdings Ltd | CNTB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2021 | Halozyme Therapeutics | HALO | Maintain | Neutral (N/A) |
|
Details | ||
| 10/29/2021 | Seagen | SGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/25/2021 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/20/2021 | Seagen | SGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/16/2021 | Repare Therapeutics | RPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/8/2021 | Aadi Bioscience Inc | AADI | New Coverage | Overweight (N/A) |
26.48 (1.58) |
-94.03% | Details | |
| 8/30/2021 | Figs Inc. | FIGS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2021 | Figs Inc. | FIGS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2021 | Figs Inc. | FIGS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2021 | Neoleukin Therapeutics | NLTX | New Coverage | Overweight (N/A) |
6.65 (3.49) |
-47.52% | Details | |
| 7/23/2021 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/6/2021 | Sensei Biotherapeutics | SNSE | Maintain | Overweight (N/A) |
|
Details | ||
| 6/21/2021 | Figs Inc. | FIGS | New Coverage | Overweight (N/A) |
36.51 (16.42) |
-55.03% | Details | |
| 5/20/2021 | Iovanace Biotherapeutics | IOVA | Downgrade | Neutral (Overweight) |
26.97 (5.13) |
-80.98% | Details | |
| 5/19/2021 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2021 | Rain Therapeutics | RAIN | New Coverage | Overweight (N/A) |
15.33 (2.80) |
-81.74% | Details | |
| 5/11/2021 | Halozyme Therapeutics | HALO | Downgrade | Neutral (Overweight) |
47.57 (67.37) |
41.62% | Details | |
| 5/11/2021 | Biomea Fusion Inc. | BMEA | New Coverage | Overweight (N/A) |
16.94 (1.39) |
-91.79% | Details | |
| 5/10/2021 | Harpoon Therapeutics | HARP | New Coverage | Overweight (N/A) |
22.04 (23.01) |
4.4% | Details | |
| 5/6/2021 | Global Blood Therapeutics | GBT | Maintain | Neutral (N/A) |
|
Details | ||
| 4/26/2021 | Achilles Therapeutics | ACHL | New Coverage | Overweight (N/A) |
16.60 (1.48) |
-91.08% | Details | |
| 4/13/2021 | Connect Biopharma Holdings Ltd | CNTB | New Coverage | Overweight (N/A) |
17.05 (2.48) |
-85.45% | Details | |
| 3/25/2021 | Marker Therapeutics | MRKR | New Coverage | Overweight (N/A) |
2.58 (1.38) |
-46.51% | Details | |
| 3/1/2021 | Sensei Biotherapeutics | SNSE | New Coverage | Overweight (N/A) |
16.29 (30.00) |
84.16% | Details | |
| 2/12/2021 | Seagen | SGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/20/2021 | Global Blood Therapeutics | GBT | Downgrade | Neutral (Overweight) |
49.92 (68.49) |
37.2% | Details | |
| 12/8/2020 | Keros Therapeutics | KROS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2020 | Keros Therapeutics | KROS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2020 | Global Blood Therapeutics | GBT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/8/2020 | Cardiff Oncology | CRDF | New Coverage | Overweight (N/A) |
12.87 (2.47) |
-80.81% | Details | |
| 10/6/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2020 | Global Blood Therapeutics | GBT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/24/2020 | Seattle Genetics | SGEN | Downgrade | Neutral (Overweight) |
176.83 (228.74) |
29.36% | Details | |
| 7/22/2020 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/14/2020 | Repare Therapeutics | RPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/8/2020 | NantKwest | NK | New Coverage | Overweight (N/A) |
11.86 (32.49) |
173.95% | Details | |
| 7/6/2020 | Immunomedics | IMMU | Maintain | Overweight (N/A) |
|
Details | ||
| 7/2/2020 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/27/2020 | Keros Therapeutics | KROS | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/27/2020 | Seattle Genetics | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/23/2020 | Immunomedics | IMMU | Maintain | Overweight (N/A) |
|
Details | ||
| 4/20/2020 | Seattle Genetics | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/7/2020 | XBiotech | XBIT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2020 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2020 | Aerie Pharma | AERI | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2020 | Seattle Genetics | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2020 | Halozyme Therapeutics | HALO | Upgrade | Overweight (Neutral) |
19.21 (67.37) |
250.7% | Details | |
| 12/11/2019 | XBiotech Inc. | XBIT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2019 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2019 | Aerie Pharma | AERI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2019 | Immunomedics | IMMU | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2019 | Clovis Oncology | CLVS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/9/2019 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2019 | Seattle Genetics | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2019 | NuCana | NCNA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/17/2019 | Seattle Genetics | SGEN | Upgrade | Overweight (Neutral) |
63.99 (228.74) |
257.46% | Details | |
| 6/28/2019 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/28/2019 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/14/2019 | XBiotech | XBIT | New Coverage | Overweight (N/A) |
7.13 (2.35) |
-67.04% | Details | |
| 5/21/2019 | Ocular Therapeutix | OCUL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2019 | Aerie Pharma | AERI | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2019 | Iovanace Biotherapeutics | IOVA | New Coverage | Overweight (N/A) |
11.02 (5.13) |
-53.45% | Details | |
| 4/15/2019 | Clovis Oncology | CLVS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/21/2019 | Aerie Pharma | AERI | New Coverage | Overweight (N/A) |
45.64 (15.25) |
-66.59% | Details | |
| 3/11/2019 | NuCana | NCNA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2019 | Immunogen Inc. | IMGN | Downgrade | Neutral (Overweight) |
4.72 (31.25) |
562.08% | Details | |
| 2/27/2019 | Clovis Oncology | CLVS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/8/2019 | Seattle Genetics | SGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/6/2019 | Stemline Therapeutics | STML | Maintain | Overweight (N/A) |
|
Details | ||
| 12/13/2018 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/26/2018 | Stemline Therapeutics | STML | New Coverage | Overweight (N/A) |
11.73 (11.83) |
0.85% | Details | |
| 11/26/2018 | CytomX Therapeutics | CTMX | New Coverage | Overweight (N/A) |
12.91 (4.68) |
-63.75% | Details | |
| 10/26/2018 | Seattle Genetics | SGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/7/2018 | Immunogen Inc. | IMGN | New Coverage | Overweight (N/A) |
10.03 (4.72) |
-52.94% | Details | |
| 9/7/2018 | Seattle Genetics | SGEN | New Coverage | Neutral (N/A) |
76.96 (63.99) |
-16.85% | Details | |
| 9/7/2018 | Catalyst Pharmaceutical Partners | CPRX | New Coverage | Overweight (N/A) |
3.40 (24.24) |
612.94% | Details | |
| 9/7/2018 | Ocular Therapeutix | OCUL | New Coverage | Overweight (N/A) |
6.82 (10.27) |
50.59% | Details |
